Darcy A. Krueger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Darcy A. Krueger has a total of 215 co-authors. Here are the top co-authors by number of shared publications:
- Mustafa Sahin
Department of Neurology, Rosamund Stone Zander Translational Neuroscience Center, Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA
16 shared publications - Jamie K. Capal
Cincinnati Children's Hospital Medical Center
8 shared publications Hope Northrup
7 shared publications- Jurriaan M. Peters
Harvard Medical School and Boston Children's Hospital Boston Massachusetts USA
7 shared publications - David M. Ritter
Division of Neurology Cincinnati Children's Hospital Medical Center Cincinnati Ohio USA
6 shared publications E. Martina Bebin
6 shared publications
Latest Publications
- Open Access
Amyloid-Independent Elevation of Plasma phosphorylated tau-217 Tracks Neurodegenerative Risk in Tuberous Sclerosis Complex: Implications for mTOR-Targeted Intervention
Background: Tuberous sclerosis complex (TSC) is a rare autosomal dominant neurodevelopmental disorder caused by loss-of-function mutations in TSC1 or TSC2, resulting in chronic hyperactivation of the mechanistic target of rapamycin (mTOR) pathway. TSC patients experience a wide spectrum of cognitive, behavioral, and psychiatric features collectively termed Tuberous Sclerosis Complex Associated Neuropsychiatric Disorders (TAND). Moreover, these patients develop a clinical trajectory in adulthood with clinical and neuropathological features overlapping those of Alzheimers disease (AD). Prior neuropathological studies have shown accumulation of AD-type mixed 3R/4R tau isoforms in adults with TSC that is amyloid-independent. Methods: To further explore the biological convergence of TSC and AD, this study compared plasma levels of phosphorylated tau-217 (ptau-217), a sensitive and specific marker of early AD pathology, in 63 TSC, 25 AD, and 116 cognitively unimpaired (CU) patients. Results: Findings revealed elevated levels of plasma ptau-217 in individuals with TSC at younger ages with a parallel age-related trajectory between TSC, AD, and CU cohorts. Multivariable linear regression showed that the log2 ptau-217 concentrations were significantly lower in the CU cohort relative to TSC (β= -0.21, SE = 0.05, p < 0.0001) but were not significantly different between the TSC and AD cohorts (β= 0.17, SE = 0.09, p < 0.071). The comparison of slopes analysis (ANCOVA) supported that the slopes for the regression of log2 ptau-217 versus age are not significantly different for the TSC and CU cohorts (TSC slope = 0.030, SE = 0.008; CU slope = 0.019, SE = 0.006; p = 0.26), nor for the TSC and AD cohorts (TSC slope = 0.030, SE = 0.01; AD slope = 0.06, SE = 0.03; p = 0.099). Conclusions: These results suggest a novel link between TSC and AD that substantiates shared downstream neurodegenerative pathways. Furthermore, these results support the potential utility of ptau-217 as a minimally invasive biomarker for TAND severity, neurodegenerative risk, and AD-like prognosis in TSC and as a tool to guide new mTOR-targeted therapeutic strategies.
Open AccessAmyloid-Independent Elevation of Plasma phosphorylated tau-217 Tracks Neurodegenerative Risk in Tuberous Sclerosis Complex: Implications for mTOR-Targeted Intervention
Background: Tuberous sclerosis complex (TSC) is a rare autosomal dominant neurodevelopmental disorder caused by loss-of-function mutations in TSC1 or TSC2, resulting in chronic hyperactivation of the mechanistic target of rapamycin (mTOR) pathway. TSC patients experience a wide spectrum of cognitive, behavioral, and psychiatric features collectively termed Tuberous Sclerosis Complex Associated Neuropsychiatric Disorders (TAND). Moreover, these patients develop a clinical trajectory in adulthood with clinical and neuropathological features overlapping those of Alzheimers disease (AD). Prior neuropathological studies have shown accumulation of AD-type mixed 3R/4R tau isoforms in adults with TSC that is amyloid-independent. Methods: To further explore the biological convergence of TSC and AD, this study compared plasma levels of phosphorylated tau-217 (ptau-217), a sensitive and specific marker of early AD pathology, in 63 TSC, 25 AD, and 116 cognitively unimpaired (CU) patients. Results: Findings revealed elevated levels of plasma ptau-217 in individuals with TSC at younger ages with a parallel age-related trajectory between TSC, AD, and CU cohorts. Multivariable linear regression showed that the log2 ptau-217 concentrations were significantly lower in the CU cohort relative to TSC (β= -0.21, SE = 0.05, p < 0.0001) but were not significantly different between the TSC and AD cohorts (β= 0.17, SE = 0.09, p < 0.071). The comparison of slopes analysis (ANCOVA) supported that the slopes for the regression of log2 ptau-217 versus age are not significantly different for the TSC and CU cohorts (TSC slope = 0.030, SE = 0.008; CU slope = 0.019, SE = 0.006; p = 0.26), nor for the TSC and AD cohorts (TSC slope = 0.030, SE = 0.01; AD slope = 0.06, SE = 0.03; p = 0.099). Conclusions: These results suggest a novel link between TSC and AD that substantiates shared downstream neurodegenerative pathways. Furthermore, these results support the potential utility of ptau-217 as a minimally invasive biomarker for TAND severity, neurodegenerative risk, and AD-like prognosis in TSC and as a tool to guide new mTOR-targeted therapeutic strategies.
- 7 July 2026
- Published by Elsevier in Pediatric Neurology
- Vol. 183, 1-9
From Infancy to Early School Age: Longitudinal Developmental Outcomes and Autism Diagnostic Stability in Tuberous Sclerosis Complex
- 7 July 2026
- Published by Elsevier in Pediatric Neurology
- Vol. 183, 1-9
From Infancy to Early School Age: Longitudinal Developmental Outcomes and Autism Diagnostic Stability in Tuberous Sclerosis Complex
- Open Access
- 5 May 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15, e91726
Closing the Gap to Interventions for Tuberous Sclerosis Complex–Associated Neuropsychiatric Disorders (TAND): Protocol for a Longitudinal Study of TAND Severity, Predictors, and Caregiver Well-Being (TANDem-2)
Background: Tuberous sclerosis complex (TSC) is a rare genetic disorder caused by pathogenic variants in the TSC1 or TSC2 genes. Apart from multisystem physical manifestations, most individuals with TSC experience TSC-associated neuropsychiatric disorders (TAND). Little is known about how TAND severity changes over time and what factors may predict these changes. Preliminary data suggest the presence of differential TAND severity trajectories. Caregiver well-being may act as a mediator of TAND severity, and a well-being intervention designed for caregivers of children with developmental disabilities may improve caregiver well-being. Objective: The study aims are to (1) examine longitudinal trajectories of TAND severity in a large sample of individuals with TSC and to examine potential predictors of differential trajectories, (2) evaluate the association between caregiver well-being characteristics, TAND severity, and severity trajectories, and (3) adapt and evaluate the feasibility, acceptability, and potential efficacy of a brief, online group–based well-being intervention for family caregivers. Methods: For the first 2 aims, 500 individuals with TSC or their caregivers will be recruited in an accelerated longitudinal design to document TAND severity at 5 time points over 12 months via a web-based app. At each time point, participants will complete demographic, TSC characteristics, intervention, and well-being questionnaires. Data will be analyzed using latent class mixed and multinomial regression modeling (aim 1) and structural equation and mediation modeling (aim 2). Participatory methods will be used to adapt an existing caregiver well-being intervention for the TSC community (aim 3). Thirty caregivers will be invited to participate in the adapted group-based online well-being intervention. Results: This study was funded from July 2024 (HT94252410790 and HT94252410791), and ethics approvals were obtained from the University of Cape Town (July 2024), Vrije Universiteit Brussel (November 2024), and the Department of Defense Office of Human Research Oversight (December 2024). The TAND Toolkit app was adapted for longitudinal data collection (aims 1 and 2). Recruitment started in December 2025 and will continue until 500 participants are enrolled (anticipated December 2026). Primary outputs are expected by July 2028. For aim 3, experiential and adaptation workshops were completed in June 2025, the pilot intervention was delivered in November 2025, and data collection will continue till May 2026. Outputs are expected by December 2026. Conclusions: Identification of differential longitudinal TAND trajectories and their correlates will stimulate research in TSC and generate evidence for the self-report quantified TAND checklist as a clinical outcome measure. Understanding the association between caregiver well-being and TAND severity will provide support for targeted well-being interventions. A successful pilot trial will provide preliminary data for larger-scale clinical trials, with the potential to support caregivers and improve TAND outcomes. Together, the findings from the study will help close the gap in interventions for TAND. Trial Registration: ClinicalTrials.gov NCT06879665; https://clinicaltrials.gov/study/NCT06879665 International Registered Report Identifier (IRRID): DERR1-10.2196/91726
- 5 May 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15, e91726
Open AccessClosing the Gap to Interventions for Tuberous Sclerosis Complex–Associated Neuropsychiatric Disorders (TAND): Protocol for a Longitudinal Study of TAND Severity, Predictors, and Caregiver Well-Being (TANDem-2)
Background: Tuberous sclerosis complex (TSC) is a rare genetic disorder caused by pathogenic variants in the TSC1 or TSC2 genes. Apart from multisystem physical manifestations, most individuals with TSC experience TSC-associated neuropsychiatric disorders (TAND). Little is known about how TAND severity changes over time and what factors may predict these changes. Preliminary data suggest the presence of differential TAND severity trajectories. Caregiver well-being may act as a mediator of TAND severity, and a well-being intervention designed for caregivers of children with developmental disabilities may improve caregiver well-being. Objective: The study aims are to (1) examine longitudinal trajectories of TAND severity in a large sample of individuals with TSC and to examine potential predictors of differential trajectories, (2) evaluate the association between caregiver well-being characteristics, TAND severity, and severity trajectories, and (3) adapt and evaluate the feasibility, acceptability, and potential efficacy of a brief, online group–based well-being intervention for family caregivers. Methods: For the first 2 aims, 500 individuals with TSC or their caregivers will be recruited in an accelerated longitudinal design to document TAND severity at 5 time points over 12 months via a web-based app. At each time point, participants will complete demographic, TSC characteristics, intervention, and well-being questionnaires. Data will be analyzed using latent class mixed and multinomial regression modeling (aim 1) and structural equation and mediation modeling (aim 2). Participatory methods will be used to adapt an existing caregiver well-being intervention for the TSC community (aim 3). Thirty caregivers will be invited to participate in the adapted group-based online well-being intervention. Results: This study was funded from July 2024 (HT94252410790 and HT94252410791), and ethics approvals were obtained from the University of Cape Town (July 2024), Vrije Universiteit Brussel (November 2024), and the Department of Defense Office of Human Research Oversight (December 2024). The TAND Toolkit app was adapted for longitudinal data collection (aims 1 and 2). Recruitment started in December 2025 and will continue until 500 participants are enrolled (anticipated December 2026). Primary outputs are expected by July 2028. For aim 3, experiential and adaptation workshops were completed in June 2025, the pilot intervention was delivered in November 2025, and data collection will continue till May 2026. Outputs are expected by December 2026. Conclusions: Identification of differential longitudinal TAND trajectories and their correlates will stimulate research in TSC and generate evidence for the self-report quantified TAND checklist as a clinical outcome measure. Understanding the association between caregiver well-being and TAND severity will provide support for targeted well-being interventions. A successful pilot trial will provide preliminary data for larger-scale clinical trials, with the potential to support caregivers and improve TAND outcomes. Together, the findings from the study will help close the gap in interventions for TAND. Trial Registration: ClinicalTrials.gov NCT06879665; https://clinicaltrials.gov/study/NCT06879665 International Registered Report Identifier (IRRID): DERR1-10.2196/91726
- 9 February 2026
- Published by Elsevier in Pediatric Neurology
- Vol. 178, 57-68
Early Vocal Development in Tuberous Sclerosis Complex Predicts Language but Not Autism Outcomes
- 9 February 2026
- Published by Elsevier in Pediatric Neurology
- Vol. 178, 57-68
Early Vocal Development in Tuberous Sclerosis Complex Predicts Language but Not Autism Outcomes
- Open Access
- 20 November 2025
- Published by Elsevier in Epilepsy & Behavior
- Vol. 174, 110740
Electrical stimulation for the induction of seizures is safe, well-tolerated and high-yield in children with drug-resistant epilepsy
- 20 November 2025
- Published by Elsevier in Epilepsy & Behavior
- Vol. 174, 110740
Open AccessElectrical stimulation for the induction of seizures is safe, well-tolerated and high-yield in children with drug-resistant epilepsy
Convolutional neural networks for automatic tuber segmentation and quantification of tuber burden in tuberous sclerosis complex
Objective: This study was undertaken to develop a fully automated algorithm for tuber segmentation and quantification of tuber volume that performs similarly to the gold standard human neuroradiologist. Methods: We used brain magnetic resonance imaging (MRI) from patients with tuberous sclerosis complex (TSC) to train and validate a convolutional neural network (CNN), which was evaluated on segmentation with the Dice–Sørensen similarity coefficient (DSSC) and on tuber burden quantification with Spearman correlation coefficient against a neuroradiologist's gold standard in the test set. Results: We collected 263 MRIs from 196 patients (57% males) with median (25th percentile–75th percentile) age of 4.3 (3.0–10.1) years: 176 MRIs in the train set, 39 in the validation set, and 48 in the test set. The final model achieved in the test set a DSSC of .820 (95% confidence interval [CI] = .799–.840) in the whole brain and in the different lobes the following: .831 (95% CI = .804–.850) in left frontal, .827 (95% CI = .799–.853) in right frontal, .817 (95% CI = .779–.842) in left temporal, .834 (95% CI = .812–.849) in right temporal, .821 (95% CI = .783–.856) in left parietal, .840 (95% CI = .810–.865) in right parietal, .832 (95% CI = .808–.851) in left occipital, and .856 (95% CI = .838–.871) in right occipital. CNN tuber volume quantification nearly perfectly correlated (Spearman correlation coefficient) with the neuroradiologist's across the whole brain (.984, 95% CI = .971–.991) and in the different lobes: .966 (95% CI = .940–.981) in left frontal, .973 (95% CI = .952–.985) in right frontal, .936 (95% CI = .888–.964) in left temporal, .967 (95% CI = .942–.982) in right temporal, .989 (95% CI = .980–.994) in left parietal, .983 (95% CI = .970–.990) in right parietal, .992 (95% CI = .985–.995) in left occipital, and .982 (95% CI = .968–.990) in right occipital (all p < .00001). Significance: We generated, trained, validated, and made publicly available a CNN that achieves a near‐perfect correlation with a neuroradiologist gold standard quantification of tuber burden, allows for objective tuber segmentation, and increases rigor and reproducibility in TSC research across institutions.
Convolutional neural networks for automatic tuber segmentation and quantification of tuber burden in tuberous sclerosis complex
Objective: This study was undertaken to develop a fully automated algorithm for tuber segmentation and quantification of tuber volume that performs similarly to the gold standard human neuroradiologist. Methods: We used brain magnetic resonance imaging (MRI) from patients with tuberous sclerosis complex (TSC) to train and validate a convolutional neural network (CNN), which was evaluated on segmentation with the Dice–Sørensen similarity coefficient (DSSC) and on tuber burden quantification with Spearman correlation coefficient against a neuroradiologist's gold standard in the test set. Results: We collected 263 MRIs from 196 patients (57% males) with median (25th percentile–75th percentile) age of 4.3 (3.0–10.1) years: 176 MRIs in the train set, 39 in the validation set, and 48 in the test set. The final model achieved in the test set a DSSC of .820 (95% confidence interval [CI] = .799–.840) in the whole brain and in the different lobes the following: .831 (95% CI = .804–.850) in left frontal, .827 (95% CI = .799–.853) in right frontal, .817 (95% CI = .779–.842) in left temporal, .834 (95% CI = .812–.849) in right temporal, .821 (95% CI = .783–.856) in left parietal, .840 (95% CI = .810–.865) in right parietal, .832 (95% CI = .808–.851) in left occipital, and .856 (95% CI = .838–.871) in right occipital. CNN tuber volume quantification nearly perfectly correlated (Spearman correlation coefficient) with the neuroradiologist's across the whole brain (.984, 95% CI = .971–.991) and in the different lobes: .966 (95% CI = .940–.981) in left frontal, .973 (95% CI = .952–.985) in right frontal, .936 (95% CI = .888–.964) in left temporal, .967 (95% CI = .942–.982) in right temporal, .989 (95% CI = .980–.994) in left parietal, .983 (95% CI = .970–.990) in right parietal, .992 (95% CI = .985–.995) in left occipital, and .982 (95% CI = .968–.990) in right occipital (all p < .00001). Significance: We generated, trained, validated, and made publicly available a CNN that achieves a near‐perfect correlation with a neuroradiologist gold standard quantification of tuber burden, allows for objective tuber segmentation, and increases rigor and reproducibility in TSC research across institutions.
- Open Access
- 21 October 2025
- Published by Elsevier in Pediatric Neurology
- Vol. 174, 86-90
Limited Utility for Head Ultrasounds in the Evaluation of Tuberous Sclerosis Complex
- 21 October 2025
- Published by Elsevier in Pediatric Neurology
- Vol. 174, 86-90
Open AccessLimited Utility for Head Ultrasounds in the Evaluation of Tuberous Sclerosis Complex
- 8 July 2025
- Published by SAGE Publications in Journal of Child Neurology
- Vol. 41 (1) , 60-67
Electroencephalogram (EEG) Spike Metrics Discriminate Impending Epileptic Spasms From Other Seizures in Children With Tuberous Sclerosis Complex: A Pilot Study
In data from a multicenter prospective observational study, we assessed whether interictal epileptiform discharge metrics in the pre-seizure onset surveillance scalp electroencephalograms (EEGs) in children with tuberous sclerosis complex could predict seizure outcomes, specifically epileptic spasms. In 16 children with eligible EEG data (7 with epileptic spasms and 9 with other seizure types) and 16 controls, 2 spike metrics were calculated through automated detection followed by expert review: (1) spike rate (spikes per minute) and (2) number of unique spike foci. In patients who developed seizures, a combination of spike rate threshold of ≥2 per minute and ≥2 unique spike foci during sleep was highly predictive of impending epileptic spasms (100% positive predictive value, 2 false negatives). One control patient was falsely predicted to develop epileptic spasms, decreasing the overall positive predictive value to 83.3%. These findings suggest that EEG spike metrics could predict impending epileptic spasms in children with tuberous sclerosis complex, pending larger-scale validation.
- 8 July 2025
- Published by SAGE Publications in Journal of Child Neurology
- Vol. 41 (1) , 60-67
Electroencephalogram (EEG) Spike Metrics Discriminate Impending Epileptic Spasms From Other Seizures in Children With Tuberous Sclerosis Complex: A Pilot Study
In data from a multicenter prospective observational study, we assessed whether interictal epileptiform discharge metrics in the pre-seizure onset surveillance scalp electroencephalograms (EEGs) in children with tuberous sclerosis complex could predict seizure outcomes, specifically epileptic spasms. In 16 children with eligible EEG data (7 with epileptic spasms and 9 with other seizure types) and 16 controls, 2 spike metrics were calculated through automated detection followed by expert review: (1) spike rate (spikes per minute) and (2) number of unique spike foci. In patients who developed seizures, a combination of spike rate threshold of ≥2 per minute and ≥2 unique spike foci during sleep was highly predictive of impending epileptic spasms (100% positive predictive value, 2 false negatives). One control patient was falsely predicted to develop epileptic spasms, decreasing the overall positive predictive value to 83.3%. These findings suggest that EEG spike metrics could predict impending epileptic spasms in children with tuberous sclerosis complex, pending larger-scale validation.
- Open Access
- 2 July 2025
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 197 (11) , e64175
Maternal Sirolimus Treatment Reverses Cardiac Rhabdomyoma‐Induced Hydrops Fetalis in a Twin Gestation With Tuberous Sclerosis Complex
Cardiac rhabdomyomas are often the presenting sign of tuberous sclerosis complex (TSC). Prior reports have shown that maternal sirolimus treatment can reduce rhabdomyomas. We used maternal sirolimus to reverse hydrops fetalis due to a massive cardiac rhabdomyoma in a twin gestation. This expands the possibilities of prenatal medical treatment in TSC.
- 2 July 2025
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 197 (11) , e64175
Open AccessMaternal Sirolimus Treatment Reverses Cardiac Rhabdomyoma‐Induced Hydrops Fetalis in a Twin Gestation With Tuberous Sclerosis Complex
Cardiac rhabdomyomas are often the presenting sign of tuberous sclerosis complex (TSC). Prior reports have shown that maternal sirolimus treatment can reduce rhabdomyomas. We used maternal sirolimus to reverse hydrops fetalis due to a massive cardiac rhabdomyoma in a twin gestation. This expands the possibilities of prenatal medical treatment in TSC.